Scientific Partnerships

Generating Innovation Through Collaboration

The complexity of brain diseases requires a concerted effort. We are committed to advancing science, from innovations born in house or externally, to develop new and better treatment options. We partner with mission-similar stakeholders to accelerate our efforts because our success – our patient’s success – depends on it.

Our Focus in Partnering

Lundbeck is a member of several scientific, multi-disciplinary partnerships with an array of stakeholders. Our focus is on contributing to future strategic directions as well as generating enablers that: 

 

  • Generate new scientific insight
  • Develop platforms, tools, and standards to support drug discovery and development
  • Create synergy and networks among key stakeholders 
  • Provide complementary competencies to our own capabilities 

Today Lundbeck is recognized as an attractive partner within brain diseases and we use it as a stepping stone to create value. We continue our internal research and activities across the value chain and supplement with external collaborations. In fact, if we look at the success we have today and have had for the last 20 years, collaborations and partnerships have played an important role.

A Global, Networked Ecosystem

Lundbeck’s long experience and continuous work within diseases of the brain has provided us with a strong global network in preclinical and clinical neuroscience research. Our partners represent expertise from several scientific areas and are typically from academia, health organizations, regulatory authorities, patient groups, scientific and medical societies, and the pharmaceutical/biotech industry.

 

Partnerships provide Lundbeck with the opportunity to exchange expertise and insights that can support joint strategic projects. Depending on the scope, a partnership can provide access to, for example, research assays, biomarkers, validated clinical outcome measures (including digital tools), large databases, in addition to valuable networks.  

 

The partnerships are typically created around a common goal where all partners contribute with human resources. Industry and society partners may also contribute with financial resources. Partnerships normally run for a period of 2-5 years. 

Our Partners

Lundbeck collaborates with companies, academic institutions, individuals, and third parties from around the world:

23andMe

IBM Watson

University of Glasgow

Alzheimer's Disease Neuroimaging Initiative

The Michael J. Fox Foundation

PD-Mito UANT

PHAG

CERVEAU

Massachusetts Life Sciences Center

NYU

Critical Path Institute

Alzheimer's Association

Wellcome

Mindstrong

Radar-CNS

Imprind

Ubiquent

Priamal

Confo

ImmunoBrain

Otsuka

Takeda

Mochida Pharmaceutical Co., Ltd.

Teva

Merck

CMS

Merz

Ovation

Chelsea Therapeutics

Prexton

Abide Therapeutics

Alder Biopharmaceuticals

More from lundbeck

Research and Development

R&D of new and improved treatments is at the core of what we do.

Clinical Data Sharing

Our policy for scientific publications and responsible clinical data sharing.

Pipeline

Discover our projects and compounds in development.